Beaming Up: CEO John Evans on the Future of Base Editing

Beam Therapeutics is benefiting from the surging interest in CRISPR-based therapies, but believes it has some key advantages when it comes to precision genome editing.

In a wide-ranging conversation, CEO John Evans discussed Beam’s pipeline and other preclinical programs. He described the improved safety profile of genome editing therapies, and talked about Beam’s multi-faceted approach when it comes to finding the right delivery vehicle. Evans also talked about Beam’s relationship with Prime Medicine, another David Liu-founded entity, which announced its launch shortly after this interview was recorded with a series A/B round of $315 million . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleGenentech’s Greener Bioprocessing Involves a New Ecosystem
Next articleSARS-CoV-2-Blocking Nanobodies Can Handle Mutations, Take the Heat